PDCD1 and neoplasm: PD-1 expression is upregulated in activated T cells, whereas its dominant ligand PD-L1 is primarily expressed on tumor cells following exposure to pro-inflammatory cytokines in the tumor microenvironment, resulting in adaptive immune resistance [6, 8].